The use of semaglutide (Ozempic) was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in ...

Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed ...

The FDA has now resolved the shortages of Novo Nordisk and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can ...

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...

A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

Adults with type 2 diabetes may have a higher risk for developing nonarteritic anterior ischemic optic neuropathy while using ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

Shares of Hims & Hers Health ( HIMS -24.30%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost ...

The shortage of semaglutide injections (Ozempic, Wegovy) is over, the FDA announced on Friday. The agency, along with maker ...